- Home
- SNN vs MRNA Comparison
SNN vs MRNA Comparison
Compare SNN & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNN | MRNA |
|---|---|---|
| Founded | 1856 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 11.5B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SNN | MRNA |
|---|---|---|
| Price | $32.20 | $30.05 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 14 |
| Target Price | $32.83 | ★ $33.25 |
| AVG Volume (30 Days) | 497.0K | ★ 9.8M |
| Earning Date | 03-02-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | ★ 59.91 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $5,944,000,000.00 | $2,232,000,000.00 |
| Revenue This Year | $7.78 | N/A |
| Revenue Next Year | $5.13 | $0.77 |
| P/E Ratio | $28.10 | ★ N/A |
| Revenue Growth | ★ 5.35 | N/A |
| 52 Week Low | $23.69 | $22.28 |
| 52 Week High | $38.79 | $48.92 |
Technical Indicators
Market Signals| Indicator | SNN | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 68.04 |
| Support Level | $32.97 | $26.90 |
| Resistance Level | $33.60 | $30.44 |
| Average True Range (ATR) | 0.42 | 1.20 |
| MACD | 0.06 | 0.59 |
| Stochastic Oscillator | 8.65 | 94.70 |
Price Performance
Historical ComparisonAbout SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.